Még nem toboroz
A Study of KMV002 in Patients With mAPMR Prostate Cancer
NCT07866300· 1. fázis· Chimivac INC· Forrás
Toboroz
A Study of JNJ-78934804 in Participants With Moderately to Severely Active Ulcerative Colitis
NCT07577856· 3. fázis· Janssen Research & Development, LLC· Forrás
Toboroz
A Study of JNJ-78934804 in Participants With Moderately to Severely Active Crohn's Disease
NCT07577843· 3. fázis· Janssen Research & Development, LLC· Forrás
Toboroz
A Study to Evaluate the Safety, Tolerability, and Efficacy of Pumitamig Alone or in Combination With Other Agents in Participants With Advanced Renal Cell Carcinoma (RCC) (ROSETTA RCC-208)
NCT07293351· 1/2. fázis· Bristol-Myers Squibb· Forrás
Toboroz
Symbiotic-GU-06: A Study to Learn About PF-08634404 Alone or In Combination With Enfortumab Vedotin in Urothelial Cancer
NCT07421700· 1/2. fázis· Pfizer· Forrás
Toboroz
A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
NCT07174336· 3. fázis· Eli Lilly and Company· Forrás
Toboroz
A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract
NCT07218380· 3. fázis· Eli Lilly and Company· Forrás
Toboroz
Phase 2/3 Trial of Izalontamab Brengitecan vs Platinum-based Chemotherapy for Metastatic Urothelial Cancer With Disease Progression on or After Immunotherapy
NCT07106762· 2/3. fázis· Bristol-Myers Squibb· Forrás
Toboroz
A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)
NCT06926868· 2/3. fázis· Bristol-Myers Squibb· Forrás
Toboroz
This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.
NCT06758401· 3. fázis· Pfizer· Forrás
Toboroz
A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors
NCT07020221· 1/2. fázis· Verastem, Inc.· Forrás
Fut, nem toboroz
A Trial of HRS-5041-103 to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of HRS-5041 in Subjects With Metastatic Castration-resistant Prostate Cancer
NCT06830850· 1. fázis· Atridia Pty Ltd.· Forrás
Toboroz
A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)
NCT06943872· 3. fázis· BeOne Medicines· Forrás
Toboroz
The AIRTIVITY™ Study: A Study to Find Out Whether BI 1291583 Helps People With Bronchiectasis
NCT06872892· 3. fázis· Boehringer Ingelheim· Forrás
Toboroz
A Study to Evaluate the Adverse Events, and Efficacy of Intravenous (IV) of Telisotuzumab Adizutecan in Combination With IV Oxaliplatin, Fluorouracil, Folinic Acid/Leucovorin, Bevacizumab, Panitumumab in Adult Participants With Metastatic Colorectal Cancer
NCT06820463· 2. fázis· AbbVie· Forrás
Fut, nem toboroz
Phase 3 Study of Xaluritamig vs Cabazitaxel or Second Androgen Receptor-Directed Therapy in Participants With Progressive Metastatic Castration-Resistant Prostate Cancer (XALute)
NCT06691984· 3. fázis· Amgen· Forrás
Toboroz
A Study of JNJ-90301900 in Combination With Chemoradiation Followed by Consolidation Immunotherapy for Non-Small Cell Lung Cancer (NSCLC)
NCT06667908· 2. fázis· Johnson & Johnson Enterprise Innovation Inc.· Forrás
Toboroz
A Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric Cancer
NCT06532006· 3. fázis· Shanghai Henlius Biotech· Forrás
Toboroz
Phase 1/ Phase 2 Study to Assess Safety and Efficacy of Orally Administered JBI-802 in Subjects With Myeloproliferative Neoplasms (MPN) and Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN) With Thrombocytosis
NCT07612280· 1/2. fázis· Jubilant Therapeutics Inc.· Forrás
Fut, nem toboroz
A Follow-up Study to Test Long-term Treatment With Nerandomilast in People With Pulmonary Fibrosis Who Took Part in a Previous Study With Nerandomilast
NCT06238622· 3. fázis· Boehringer Ingelheim· Forrás
Fut, nem toboroz
EASi-KIDNEY™ (The Studies of Heart & Kidney Protection With BI 690517 in Combination With Empagliflozin)
NCT06531824· 3. fázis· Boehringer Ingelheim· Forrás
Toboroz
First in Human (FIH) Study of ALN-SOD in Adult Participants With Amyotrophic Lateral Sclerosis Associated With Mutation in the SOD1 Gene (SOD1-ALS)
NCT06351592· 1/2. fázis· Regeneron Pharmaceuticals· Forrás
Fut, nem toboroz
A Study of AMG 732 in Healthy Participants and Participants With Thyroid Eye Disease
NCT06401044· 1/2. fázis· Amgen· Forrás
Fut, nem toboroz
Study of GS-1427 in Participants With Moderately to Severely Active Ulcerative Colitis
NCT06290934· 2. fázis· Gilead Sciences· Forrás
Fut, nem toboroz
Ryme Medical TLD Pilot Study
NCT05967091· Ryme Medical, Inc.· Forrás
Toboroz
An Evaluation of the AeriSeal System for CONVERTing Collateral Ventilation Status in Patients With Severe Emphysema
NCT06035120· Pulmonx Corporation· Forrás
Toboroz
A Study Evaluating FMC-376 in Participants With KRAS G12C Mutated Solid Tumors
NCT06244771· 1/2. fázis· Frontier Medicines Corporation· Forrás
Toboroz
BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors
NCT06120283· 1. fázis· BeOne Medicines· Forrás
Fut, nem toboroz
Disitamab Vedotin With Pembrolizumab vs Chemotherapy in Previously Untreated Urothelial Cancer Expressing HER2
NCT05911295· 3. fázis· Seagen, a wholly owned subsidiary of Pfizer· Forrás
Toboroz
IKS014 in Advanced Solid Tumors That Express HER2
NCT05872295· 1. fázis· Iksuda Therapeutics Ltd.· Forrás
Fut, nem toboroz
Clairleafᵀᴹ: A Study to Test Long-term Treatment With BI 1291583 in People With Bronchiectasis Who Took Part in a Previous Study With This Medicine
NCT05846230· 2. fázis· Boehringer Ingelheim· Forrás
Fut, nem toboroz
A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With RAS Q61X Mutations
NCT05907304· 1. fázis· Erasca, Inc.· Forrás
Toboroz
Combination of 177Lu-TLX250 and Peposertib in Patients With Carbonic Anhydrase IX -Expressing Solid Tumors
NCT05868174· 1. fázis· Telix Pharmaceuticals (Innovations) Pty Limited· Forrás
Toboroz
A Study of Pasritamig (JNJ-78278343) in Combination With Other Agents for Metastatic Prostate Cancer
NCT05818683· 1. fázis· Janssen Research & Development, LLC· Forrás
Fut, nem toboroz
Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Participants With Metastatic Breast Cancer
NCT05563220· 1/2. fázis· Stemline Therapeutics, Inc.· Forrás
Toboroz
FORAGER-1: A Study of Vepugratinib (LY3866288; LOXO-435) in Participants With Cancer With a Change in a Gene Called FGFR3
NCT05614739· 1. fázis· Eli Lilly and Company· Forrás
Fut, nem toboroz
Safety and Preliminary Anti-Tumor Activity of TYRA-300 in Advanced Urothelial Carcinoma and Other Solid Tumors With FGFR3 Gene Alterations
NCT05544552· 1/2. fázis· Tyra Biosciences, Inc· Forrás
Meghívásos bevonás
Extension Study of Inhaled Treprostinil in Subjects With Fibrotic Lung Disease
NCT04905693· 3. fázis· United Therapeutics· Forrás
Toboroz
A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2
NCT04879329· 2. fázis· Seagen, a wholly owned subsidiary of Pfizer· Forrás
Fut, nem toboroz
A Study of Abemaciclib (LY2835219) With Abiraterone in Men With Prostate Cancer That Has Spread to Other Parts of the Body and is Expected to Respond to Hormonal Treatment (Metastatic Hormone-Sensitive Prostate Cancer)
NCT05288166· 3. fázis· Eli Lilly and Company· Forrás
Toboroz
Polysomnographic Titration of Non-invasive Ventilation in Motor Neurone Disease
NCT05136222· University of Melbourne· Forrás
Fut, nem toboroz
Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing
NCT05059522· 3. fázis· Pfizer· Forrás
Fut, nem toboroz
A Beta-only IL-2 ImmunoTherapY Study
NCT05086692· 1/2. fázis· Medicenna Therapeutics, Inc.· Forrás
Fut, nem toboroz
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study of Fuzuloparib Combined With Abiraterone Acetate and Prednisone (AA-P) Versus Placebo Combined With AA-P as First-Line Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer
NCT04691804· 3. fázis· Jiangsu HengRui Medicine Co., Ltd.· Forrás
Meghívásos bevonás
A Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label Extension
NCT03683186· 3. fázis· United Therapeutics· Forrás
Fut, nem toboroz
A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Participants With Metastatic Prostate Cancer
NCT03748641· 3. fázis· Janssen Research & Development, LLC· Forrás
Fut, nem toboroz
A Study of Abiraterone Acetate Plus Prednisone With or Without Abemaciclib (LY2835219) in Participants With Prostate Cancer
NCT03706365· 2/3. fázis· Eli Lilly and Company· Forrás
Toboroz
International Registry for Men With Advanced Prostate Cancer (IRONMAN)
NCT03151629· Prostate Cancer Clinical Trials Consortium· Forrás
Fut, nem toboroz
Safety and Efficacy Study of Enzalutamide Plus Leuprolide in Patients With Nonmetastatic Prostate Cancer (EMBARK)
NCT02319837· 3. fázis· Pfizer· Forrás